About Finerenone API

Mechanism of Action

Finrenone is a selective mineralocorticoid receptor antagonist (MRA) used in the treatment of heart failure with preserved ejection fraction (HFpEF). It works by blocking the effects of mineralocorticoids, such as aldosterone, at the mineralocorticoid receptor in the distal nephron of the kidney. This results in increased excretion of salt and water and a reduction in blood volume, leading to a decrease in ventricular preload and afterload and improvement in cardiac function.

Mineralocorticoids are naturally occurring hormones that regulate electrolyte and fluid balance in the body. In patients with heart failure, elevated levels of aldosterone can contribute to the development and progression of the disease by promoting fluid and salt retention, oxidative stress, and inflammation. By blocking the actions of aldosterone, finrenone helps to counteract these effects and improve cardiac function in patients with HFpEF.

Indication

Finerenone is indicated for the treatment of adult patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure in which the heart muscle is unable to pump blood effectively, despite the left ventricle being able to contract and relax normally. It is estimated to affect about half of all heart failure patients and is associated with significant morbidity and mortality.

The use of finerenone in the treatment of HFpEF is based on its ability to selectively block the mineralocorticoid receptor and reduce fluid and salt retention in the body. This results in a reduction in blood volume and improvement in cardiac function, which can help to relieve symptoms and improve quality of life in patients with HFpEF.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Finerenone API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Finerenone API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.